Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
June 3, 2019 Off

Sensorion Announces Poster Presentation at the “Société Internationale d’Otoneurologie” Symposium

By BusinessWire

Presentation of SENS-111 phase 2 study protocol in Acute Unilateral Vestibulopathy (AUV) MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN)…

June 3, 2019 Off

Xolair (Omalizumab) Significantly Reduced Nasal Polyps and Congestion Symptoms in Adults with Chronic Rhinosinusitis with Nasal Polyps in Two Phase III Studies

By BusinessWire

– The Phase III POLYP 1 and POLYP 2 studies of Xolair in adults with chronic rhinosinusitis with nasal polyps…

June 3, 2019 Off

Reviva Pharmaceuticals Announces Successful Completion of Pre-IND Meeting with FDA on Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

By BusinessWire

CUPERTINO, Calif.–(BUSINESS WIRE)–Reviva Pharmaceuticals, Inc. (Reviva), a privately held, clinical stage pharmaceutical company today announced that it has successfully completed…

June 3, 2019 Off

Lyndra Therapeutics Welcomes Dr. Patricia Hurter as Chief Executive Officer

By BusinessWire

Addition to management team strengthens Lyndra’s development capabilities WATERTOWN, Mass.–(BUSINESS WIRE)–#CEO–Lyndra Therapeutics, the company making daily pills a thing of…

June 3, 2019 Off

Takeda Makes First Private Sector Pledge for Global Fund Replenishment

By BusinessWire

GENEVA & OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today became the first private sector company to announce a…

June 2, 2019 Off

Study Investigating Darzalex®▼ (daratumumab) Shows Improved Depth of Response and Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant

By BusinessWire

• Pivotal Phase 3 data presented in ASCO oral session and simultaneously published in The Lancet • The Phase 3…

June 2, 2019 Off

Phase 3 COLUMBA Study Investigating a Subcutaneous Formulation of Darzalex®▼ (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma

By BusinessWire

Subcutaneous formulation also showed reduced administration time and lower rates of infusion-related reactions compared to intravenous administration BEERSE, Belgium–(BUSINESS WIRE)–The…

June 2, 2019 Off

Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019

By BusinessWire

Investigational treatment demonstrates favorable early safety and efficacy data in patients who had received a median five prior treatments including…

June 2, 2019 Off

Celgene Presents Data from a Phase 1/2 Clinical Study of Iberdomide in Combination with Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma at ASCO 2019

By BusinessWire

Investigational treatment demonstrates favorable early safety and efficacy data in patients who had received a median five prior treatments including…

June 2, 2019 Off

Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting

By BusinessWire

Integrated efficacy and safety results in 643 patients were consistent with individual trial results (ADVANCE and RECOVER) The integrated data…

Posts pagination

Previous 1 … 3,143 3,144 3,145 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine